SPAR Group, Inc. (SGRP) today announced its financial results for the second quarter 2012. Company revenues were $24.3 million, with gross profit of $6.7 million and net income attributable to SPAR Group, Inc. of $718,000. For the six months of 2012 SPAR achieved revenue of $45.4 million, gross profit of $12.5 million and diluted earnings […]
APS Enthusiasts, What The F* Are You Doing?
All pinky market is holding its breath – APS’s (AwesomePennyStocks) new pick is coming! Penny traders are riveting with excitment! Copycats emails are flooding traders’ mailboxes. Today, for example, Aquentium, Inc. (AQNM), as a new PennyPic alert, has been brought to you by pennymafia. AQNM stock quickly rose for over 100% gains and dropped faster […]
Implant Sciences (IMSC): Significant ROI Ahead
Our new investment opportunity with at least 100% ROI (return on investment) in short-term is Implant Sciences Corp. (IMSC) Implant Sciences develops and manufactures explosive trace detection sensors and systems that are capable of detecting minute amounts of a wide variety of military, commercial, and homemade explosives. IMSC’s patented technologies provide unique screening capabilities to […]
New Investment Opportunity in Defense Products Company
We love stocks for companies in healthcare sector, both in biotech and medical appliances industries, especially if these companies develop or already marketing their innovative products. Your investment here, particularly at early stages, not just helps increasing the companies’ financial flexibility for developing a new world-shattering drug and/or revolutionary medical device, but also offers the […]
Trading Opportunity with Systems America, Inc. (SYAI)
Systems America, Inc. (SYAI) announced today after market hours that company received notice that Pink OTC Markets finished the processing the Company’s 2011 Annual Report and two reports for the quarters of 2012. As the result the Pink Sheets “Current Information” tier will be applied to the SYAI on July 25, 2012. Also Systems America is […]
Astex Pharmaceuticals (ASTX): EMA Recommends DACOGEN Approval in the EU
Astex Pharmaceuticals, Inc. (ASTX) today announced that Janssen-Cilag International NV, who holds marketing and development rights for DACOGEN™ in all markets except the North America, was notified that the CHMP (Committee for Medical Products for Human Use) of the EMA (European Medicines Agency) granted a positive opinion recommending approval of DACOGEN™ for injection in the […]
pSivida Corp. (PSDV): ILUVIEN MA Granted vs $40M Equity Financing
pSivida Corp. (PSDV) today announced the National Security Agency of Medicines and Health Products (L’Agence Nationale de Sécurité du Médicament et des Produits de Santé) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Dr. Paul Ashton, President and […]
Nokia Corporation (NYSE: NOK): A few Things to Consider
Nokia Corporation (NYSE: NOK) today announced the interim financial report for the Q2 2012 Nokia net sales in Q2 2012 were EUR 7.5 billion, up from EUR 7.4 billion in Q1 2012 Nokia Devices & Services Q2 net sales decreased 5% quarter-on-quarter. Lumia Q2 volumes increased quarter-on-quarter to 4 million units. Mobile Phones Q2 volumes […]
Somaxon Pharmaceuticals (SOMX): Settlement with Mylan and Par Pharmaceutical
Somaxon Pharmaceuticals (SOMX) announced yesterday’s, after market closet, hat it has entered into separate settlement arrangements with Mylan Inc. and its subsidiary, Mylan Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc. to resolve pending patent litigation involving Silenor(R) 3 mg and 6 mg tablets. The settlement agreement with Mylan grants […]
StemCells, Inc. (STEM): Positive Alzheimer’s Disease Study Results
StemCells, Inc. (STEM) today announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer’s disease (AD). The research was conducted in collaboration with a world-renowned leader in AD, Frank LaFerla, Ph.D., Director of the University of California, Irvine (UCI) Institute for […]